Pfizer Inc  has announced that its bivalent respiratory syncytial virus (RSV) vaccine candidate showed an efficacy of 81.8% against hospitalization in infants from birth through the first 90 days of life. Against this backdrop, positive conversations among Twitter influencers around ‘RSV Vaccine’ shot up dramatically, finds the Social Media Analytics Platform of GlobalData, a leading data and analytics platform company.

Smitarani Tripathy, Social Media Analyst at GlobalData, comments: “Influencers from the pharma industry are positive on the news as they are of the opinion that the RSV vaccine will offer maternal protection and reduce the risk of infection in infants against one of the deadliest respiratory viruses. Few Twitter influencers expect RSV vaccine will be a game changer if it gets the FDA approval as the vaccine is likely to save more lives and a better option than COVID-19 vaccine for kids.”

Below are a few popular tweets on “RSV Vaccine” captured by the GlobalData’s Social Media Analytics Platform:

1. Chise, American Senior Scientist in Vaccine Research and Development:

“This is HUGE news! Pfizer’s bivalent Respiratory Syncytial Virus (RSV) vaccine candidate (RSVpreF) demonstrated stellar efficacy (81.8% against SEVERE lower respiratory illness). Pfizer plans to submit by end of this year! If approved, this will be THE FIRST RSV vaccine!”

2. Zeynep Tufekci, Professor at Columbia University in the City of New York:

“Great news: good results for the RSV vaccine offering maternal protection *and* to the infant in their first three months. The trial in the elderly has recently readout as well, great results there, too. RSV has long been a great threat—especially to young kids and the elderly.”

3. Celine Gounder, Senior Fellow & Editor-at-Large for Public Health at KHN:

“6/ It will also be interesting to see the results of the adult RSV vaccine study. RSV kills ~14K adults 65+ in the U.S. per year. It’s the #3 deadliest viral respiratory infection in adults after COVID and influenza.”

4. Elizabeth Murray, Physician at University of Rochester Medical Center

“Great explanation of the proposed RSV vaccine and why it’s been so hard to develop. Now that scientists understand this tricky F protein, they are able to target it to induce protection. Fabulous news, decades in the making.”

5. Nicole Saphire, Radiologist & Director of Breast Imaging at MSK Monmouth:

“When it comes to young kids, an RSV vaccine makes infinitely more sense than a Covid vaccine.”

6. Derek Thompson, Writer at The Atlantic,

“Whoa. Pfizer reporting positive data from Phase 3 trials of RSV vaccines for mothers—which reduces severe disease in infants.This winter has been one of the worst RSV breakouts in years. Approval would be a game-changer and a life-saver.”

7. Monica Gandhi, Professor of Medicine at UCSF:

“RSV vaccine also tested in a phase 3 trial with 65 and older individuals and positive findings for protection – traditional protein-based vaccine. Likely available for older individuals and pregnant women to protect newborns by next fall.”